|
Eine Ebene nach oben |
Gruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 6
Zeitschriftenartikel
Dent, S.; Cortes, J.; Im, Y.-H.; Dieras, V.; Harbeck, N.; Krop, I. E.; Wilson, T. R.; Cui, N.; Schimmoller, F.; Hsu, J. Y.; He, J.; De Laurentiis, M.; Sousa, S.; Drullinsky, P. und Jacot, W.
(2021):
Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial.
In: Annals of Oncology, Bd. 32, Nr. 2: S. 197-207
Rugo, H. S.; Dieras, V.; Gelmon, K. A.; Finn, R. S.; Slamon, D. J.; Martin, M.; Neven, P.; Shparyk, Y.; Mori, A.; Lu, D. R.; Bhattacharyya, H.; Bartlett, C. Huang; Iyer, S.; Johnston, S.; Ettl, J. und Harbeck, N.
(2018):
Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial.
In: Annals of Oncology, Bd. 29, Nr. 4: S. 888-894
Cardoso, F.; Senkus, E.; Costa, A.; Papadopoulos, E.; Aapro, M.; Andre, F.; Harbeck, N.; Aguilar Lopez, B.; Barrios, C. H.; Bergh, J.; Biganzoli, L.; Börs-Doers, C. B.; Cardoso, M. J.; Carey, L. A.; Cortes, J.; Curigliano, G.; Dieras, V.; El Saghir, N. S.; Eniu, A.; Fallowfield, L.; Francis, P. A.; Gelmon, K.; Johnston, S. R. D.; Kaufmann, B.; Koppikar, S.; Krop, I. E.; Mayer, M.; Nakigudde, G.; Offersen, B. V.; Ohno, S.; Pagani, O.; Paluch-Shimon, S.; Penault-Llorca, F.; Prat, A.; Rugo, H. S.; Sledge, G. W.; Spence, D.; Thomssen, C.; Vorobiof, D. A.; Xu, B.; Norton, L. und Winer, E. P.
(2018):
4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4).
In: Annals of Oncology, Bd. 29, Nr. 8: S. 1634-1657
Dieras, V.; Harbeck, N.; Joy, A. A.; Gelmon, K. A.; Ettl, J.; Verma, S.; Lu, D.; Gauthier, E. R.; Schnell, P.; Mori, A.; Rugo, H. S. und Finn, R. S.
(2017):
PALOMA-2: Neutropenia (NP) patterns in patients (Pts) with estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-) first-line advanced breast cancer (ABC) receiving palbociclib plus letrozole (P plus L).
In: Annals of Oncology, Bd. 28
Rugo, H.; Dieras, V.; Gelmon, K. A.; Finn, R.; Slamon, D.; Miguel, M.; Neven, P.; Ettl, J.; Shparyk, Y.; Mori, A.; Lu, D. R.; Bhattacharyya, H.; Bartlett, C. H.; Iyer, S.; Johnston, S. und Harbeck, N.
(2016):
Impact of palbociclib plus letrozole on health related quality of life (HRQOL) compared with letrozole alone in treatment naive postmenopausal patients with ER+HER2-metastatic breast cancer (MBC): results from PALOMA-2.
In: Annals of Oncology, Bd. 27
Baselga, J.; Cortes Castan, J.; De Laurentiis, M.; Dieras, V.; Harbeck, N.; Hsu, J.; Jin, H.; Schimmoller, F.; Wilson, T. R.; Im, Y.-H.; Jacot, W.; Krop, I. E. und Verma, S.
(2016):
SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumours.
In: Annals of Oncology, Bd. 27